Inventor · disambiguated record
Qiuchuan Zhuang
Also filed as: ZHUANG QIUCHUAN
8 granted patents·13 pending applications·34 citations·filing 2016–2024
82Inventor score
Top patents by PatentIndex Score
21 records- 0194US10934363B2Chimeric antigen receptors based on single domain antibodies and methods of use thereofLEGEND BIOTECH USA INC·Filed 2016·Granted Mar 2, 2021·24 cites·24 claims
- 0293US11186647B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Granted Nov 30, 2021·4 cites·21 claims
- 0388US12351638B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Granted Jul 8, 2025·1 cites·8 claims
- 0485US11535677B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2017·Granted Dec 27, 2022·3 cites·26 claims
- 0582US2024409654A1Chimeric antigen receptors targeting bcma and methods of use thereofLEGEND BIOTECH USA INC·Filed 2024·Application pending·0 cites
- 0679US12258418B2Claudin18.2 binding moieties and uses thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2019·Granted Mar 25, 2025·2 cites·20 claims
- 0759US2021261675A1Chimeric antigen receptors based on single-domain antibodies and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Application pending·0 cites
- 0856US2023085615A2Engineered t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 0956US2022313738A1Nef-containing t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1055US2024316201A1Engineered immune effector cells expressing exogenously introduced cytokinesNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 1154US11401317B2Human-CD123-targeting chimeric receptor ligand and application thereofNANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Aug 2, 2022·0 cites·23 claims
- 1252US2023192883A1Cd19 binding molecules and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1352US2023250184A1Cd22 binding molecules and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1449US2023088461A1Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1548US2023058669A1Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1648US2022177524A1Nef-containing t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 1747US2023192841A1Claudin18.2 binding moieties and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1845US11564945B2Chimeric antigen receptor and use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Jan 31, 2023·0 cites·22 claims
- 1942US2019038671A1Engineered mammalian cells for cancer therapyNANJING LEGEND BIOTECH CO LTD·Filed 2017·Application pending·0 cites
- 2041US2021363218A1Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2018·Application pending·0 cites
- 2140US11827713B2Chimeric antibody immune effector cell engagers and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2018·Granted Nov 28, 2023·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Qiuchuan Zhuang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →